Literature DB >> 3508296

Expression in COS cells of a mouse-human chimaeric B72.3 antibody.

N Whittle1, J Adair, C Lloyd, L Jenkins, J Devine, J Schlom, A Raubitschek, D Colcher, M Bodmer.   

Abstract

B72.3 is a mouse hybridoma cell-line secreting an IgG1 antibody which recognises an epitope on a tumour-associated antigen, TAG-72. This high molecular weight mucin-like molecule is found on a variety of human neoplasms, including colon, breast and ovarian carcinomas. Chimaeric immunoglobulin genes with the B72.3 specificity have been constructed by joining the mouse variable regions from cDNA clones to human genomic constant regions using recombinant DNA techniques. The chimaeric heavy and light chain immunoglobulin genes were placed under the control of a strong viral promoter, and co-transfected into COS-1 cells. SDS-PAGE analysis of the 35S-labelled products demonstrated that the transiently expressed antibodies were correctly synthesised and assembled. The specific binding characteristics of the parent B72.3 antibody were retained by the chimaeric antibody in an antigen-based ELISA. This system gave sufficiently high transient expression of the chimaeric antibody molecules to allow rapid physical and immunological characterisation of the engineered gene products.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508296     DOI: 10.1093/protein/1.6.499

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  19 in total

1.  Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.

Authors:  N McCloskey; M W Turner; P Steffner; R Owens; D Goldblatt
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

2.  Genetic engineering of high affinity anti-human colorectal tumour mouse/human chimeric antibody.

Authors:  J Xiang; Z Chen
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.

Authors:  M I Cockett; C R Bebbington; G T Yarranton
Journal:  Nucleic Acids Res       Date:  1991-01-25       Impact factor: 16.971

4.  Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

Authors:  D J King; J R Adair; S Angal; D C Low; K A Proudfoot; J C Lloyd; M W Bodmer; G T Yarranton
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

5.  Relationship between cell size, cell cycle and specific recombinant protein productivity.

Authors:  D R Lloyd; P Holmes; L P Jackson; A N Emery; M Al-Rubeai
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

6.  Toward more efficient protein expression: keep the message simple.

Authors:  Stephan Kalwy; James Rance; Robert Young
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

7.  The intron requirement for immunoglobulin gene expression is dependent upon the promoter.

Authors:  M S Neuberger; G T Williams
Journal:  Nucleic Acids Res       Date:  1988-07-25       Impact factor: 16.971

8.  A humanized antibody that binds to the interleukin 2 receptor.

Authors:  C Queen; W P Schneider; H E Selick; P W Payne; N F Landolfi; J F Duncan; N M Avdalovic; M Levitt; R P Junghans; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Porcine E-selectin: cloning and functional characterization.

Authors:  Y T Tsang; P E Stephens; S T Licence; D O Haskard; R M Binns; M K Robinson
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

10.  Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.

Authors:  S L Zebedee; R K Koduri; J Mukherjee; S Mukherjee; S Lee; D F Sauer; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.